SanBio Past Earnings Performance
Past criteria checks 0/6
SanBio's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 86.7% per year.
Key information
-2.2%
Earnings growth rate
2.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -86.7% |
| Return on equity | -94.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SanBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 0 | -2,644 | 1,690 | 2,850 |
| 31 Oct 23 | 0 | -5,684 | 1,636 | 3,584 |
| 31 Jul 23 | 0 | -5,192 | 1,752 | 4,610 |
| 30 Apr 23 | 0 | -5,870 | 1,720 | 5,796 |
| 31 Jan 23 | 0 | -5,559 | 1,781 | 6,118 |
| 31 Oct 22 | 0 | -3,320 | 1,895 | 6,390 |
| 31 Jul 22 | 0 | -4,697 | 1,865 | 6,324 |
| 30 Apr 22 | 0 | -4,132 | 1,725 | 5,199 |
| 31 Jan 22 | 0 | -4,677 | 1,665 | 4,955 |
| 31 Oct 21 | 0 | -1,659 | 1,709 | 4,643 |
| 31 Jul 21 | 0 | -2,312 | 1,759 | 4,524 |
| 30 Apr 21 | 0 | -2,738 | 1,759 | 4,340 |
| 31 Jan 21 | 0 | -3,385 | 1,730 | 4,071 |
| 31 Oct 20 | 23 | -6,718 | 1,629 | 4,439 |
| 31 Jul 20 | 20 | -6,316 | 1,579 | 4,112 |
| 30 Apr 20 | 258 | -5,928 | 1,648 | 4,089 |
| 31 Jan 20 | 447 | -5,157 | 1,606 | 4,327 |
| 31 Oct 19 | 597 | -4,651 | 1,313 | 4,086 |
| 31 Jul 19 | 753 | -3,927 | 1,110 | 4,065 |
| 30 Apr 19 | 772 | -2,819 | 826 | 3,844 |
| 31 Jan 19 | 741 | -2,920 | 673 | 3,721 |
| 31 Oct 18 | 687 | -2,331 | 722 | 3,654 |
| 31 Jul 18 | 656 | -2,705 | 676 | 3,824 |
| 30 Apr 18 | 525 | -3,680 | 686 | 4,199 |
| 31 Jan 18 | 490 | -3,940 | 712 | 4,156 |
| 31 Oct 17 | 562 | -3,302 | 791 | 3,641 |
| 31 Jul 17 | 514 | -2,966 | 854 | 3,115 |
| 30 Apr 17 | 447 | -2,655 | 840 | 2,621 |
| 31 Jan 17 | 949 | -1,835 | 806 | 2,058 |
| 31 Oct 16 | 833 | -2,209 | 722 | 1,884 |
| 31 Jul 16 | 1,447 | -1,693 | 673 | 1,954 |
| 30 Apr 16 | 1,515 | -1,156 | 625 | 1,856 |
| 31 Jan 16 | 1,174 | -988 | 604 | 1,695 |
| 31 Oct 15 | 1,208 | -647 | 548 | 1,390 |
| 31 Jan 15 | 3,229 | 1,736 | 357 | 623 |
| 31 Jan 14 | 204 | -589 | 258 | 530 |
Quality Earnings: SNBI.F is currently unprofitable.
Growing Profit Margin: SNBI.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNBI.F is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare SNBI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNBI.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: SNBI.F has a negative Return on Equity (-94.7%), as it is currently unprofitable.